Cryo-Cell International Inc. (CCEL)
| Market Cap | 79.81M |
| Revenue (ttm) | 29.72M |
| Net Income (ttm) | 3.85M |
| Shares Out | 7.96M |
| EPS (ttm) | 0.48 |
| PE Ratio | 19.69 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $9.45 |
| Previous Close | $9.50 |
| Change ($) | -0.05 |
| Change (%) | -0.53% |
| Day's Open | 9.20 |
| Day's Range | 9.20 - 9.45 |
| Day's Volume | 419 |
| 52-Week Range | 6.45 - 10.10 |
OLDSMAR, Fla., July 15, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem c...
MIAMI, May 10, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell's Medical Director, Dr. Joanne Kurtzberg and her research team at The Marcus Center for Cellular Cures (MC3) at Duke University School of Medicine are c...
OLDSMAR, Fla., April 14, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem ...
About CCEL
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to p... [Read more...]
| Industry Medical Care Facilities | IPO Date Jan 21, 1997 |
| Stock Exchange OTCMKTS | Ticker Symbol CCEL |
Financial Performance
In 2020, CCEL's revenue was $31.15 million, a decrease of -2.10% compared to the previous year's $31.82 million. Earnings were $3.62 million, an increase of 58.23%.